Gene · 2042
Papers1,673
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,673
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identifying plasma proteins and immunocyte phenotypes as risk factors in rheumatoid arthritis: The role of EPHA3 and CD28+ CD45RA+ CD8br treg cells. | Clin Rheumatol | 2025 | 40751895 | PubTator, text mining | PubMed |
| A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas. | Nat Commun | 2025 | 40744913 | PubTator, text mining | PubMed |
| Development of a specific anti-human EphA3 monoclonal antibody, Ea3Mab-20, for flow cytometry. | Biochem Biophys Rep | 2025 | 40688499 | PubTator, text mining | PubMed |
| Feasibility of long-read sequencing to identify molecular alterations in an Indonesian cohort of locally advanced to advanced nasopharyngeal cancer. | Sci Rep | 2025 | 40594369 | PubTator, text mining | PubMed |
| Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal adenocarcinoma. | Front Oncol | 2025 | 40492125 | PubTator, text mining | PubMed |
| Identification of regulatory cell death-related genes during MASH progression using bioinformatics analysis and machine learning strategies. | Front Immunol | 2025 | 40406118 | PubTator, text mining | PubMed |
| Nanotechnology in cancer treatment: revolutionizing strategies against drug resistance. | Front Bioeng Biotechnol | 2025 | 40370595 | PubTator, text mining | PubMed |
| Abstracts from the 13th International Conference for Healthcare and Medical Students (ICHAMS). | BMC Proc | 2025 | 40033387 | PubTator, text mining | PubMed |
| EXPERT expands prime editing efficiency and range of large fragment edits. | Nat Commun | 2025 | 39939583 | PubTator, text mining | PubMed |
| Targeted thermosensitive liposomes loaded with gold nanoparticles and temozolomide hexadecanoate for the synergistic photothermal-chemotherapy treatment of glioblastoma. | J Pharm Sci | 2025 | 39706568 | PubTator, text mining | PubMed |
| Prediction of Lung Adenocarcinoma Driver Genes Through Protein-Protein Interaction Networks Utilizing GenePlexus. | Proteomics | 2025 | 39696915 | PubTator, text mining | PubMed |
| Altered TP53, CDKN2A, ATM, EPHA7, POT1, CHEK1, GRIN2A, and EGFR Predict Shorter Survival in Penile Squamous Cell Carcinoma. | Mod Pathol | 2025 | 39694330 | PubTator, text mining | PubMed |
| VIM-AS1, which is regulated by CpG methylation, cooperates with IGF2BP1 to inhibit tumor aggressiveness via EPHA3 degradation in hepatocellular carcinoma. | Exp Mol Med | 2024 | 39617786 | PubTator, text mining | PubMed |
| A participatory research to assess how a student citizens' assembly can facilitate the co-creation of nutrition interventions in higher education settings. | BMC Public Health | 2024 | 39390476 | PubTator, text mining | PubMed |
| Clinicopathological characteristics and genetic features of young and senior Ewing sarcoma patients. | Diagn Pathol | 2024 | 39285408 | PubTator, text mining | PubMed |
| Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy. | Int Immunopharmacol | 2024 | 39151386 | PubTator, text mining | PubMed |
| EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses. | J Immunother Cancer | 2024 | 39111833 | PubTator, text mining | PubMed |
| EphA3 CAR T cells are effective against glioblastoma in preclinical models. | J Immunother Cancer | 2024 | 39111832 | PubTator, text mining | PubMed |
| A pan-cancer analysis of EphA family gene expression and its association with prognosis, tumor microenvironment, and therapeutic targets. | Front Oncol | 2024 | 38952552 | PubTator, text mining | PubMed |
| Phosphorylated protein chip combined with artificial intelligence tools for precise drug screening. | J Biomed Res | 2024 | 38802297 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2042/papers?page=3